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Background and objective
Cysteinyl leukotrienes (LTs) contribute to airway
inflammation by interacting with type 1 and 2 cysteinyl
leukotriene receptors as well as not clearly known type
3 leukotriene receptors. In contrast to LTC4 and
LTD4, LTE4 is weak agonist at type 1 and 2 cysteinyl
leukotriene receptors. Although LTE4 plays a key role
in airway inflammation, our understanding of its
potential receptor remains unclear. We investigated the
effects of clopidogrel in the development of allergic air-
way inflammation using mouse asthma model and eosi-
nophil cell-line.
Methods
BALB/c mice were sensitized by intraperitoneal injection
of ovalbumin (OVA) on days 0 and 14, followed by 3
nebulized OVA challenges on days 28-30. On each chal-
lenge day, 30mg/kg clopidogrel was administered
through intragastric administration 30 minutes before
challenge. 48 hours after OVA challenge, mice were
assessed for airway hyperresponsiveness (AHR), cell
composition and cytokine levels in bronchoalveolar
lavage (BAL) fluid. Human eosinophil EOL-1 cells were
treated with LTE4 with or without clopidogrel, and
intracellular and extracellular eosinophil cationic protein
(ECP) expression were investigated by Western blot and
ELISA, respectively. Finally, CC ligand 5 (CCL5) levels
in BAL fluid were measured by ELISA. Our experiments
were approved by Institutional Animal Care and Use
Committee of Ajou University (IACUC #152).
Results
The administration of clopidogrel decreased AHR and
airway inflammatory cell numbers including eosinophil
in BAL fluid following OVA challenge (P<0.01, respec-
tively). These results were associated with decreased
levels of Th2 cytokines and CCL5, but not Th1 cytokine
in BAL fluid. In histological analysis, the inflammatory
cells in peribronchial and perivascular areas as well as
mucus-containing goblet cells were also decreased in
the clopidogrel administered mice compared to vehicle
treated mice (P<0.01). LTE4 stimulation decreased intra-
cellular expression of ECP but this expression was atte-
nuated by pre-treatment of clopidogrel.
Conclusions
Clopidogrel could prevent the development of AHR, air-
way inflammation, and cytokine production in allergen
challenged mice through the inhibition of eosinophilic
activation. Clopidogrel could be a novel therapeutic tar-
get for asthma treatment.
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